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Bacterial meningitis is a life-threatening illness that results from bacterial infection of the meninges and is associated with high
mortality and morbidity rate, especially when the Streptococcus pneumoniae is the causative agent. Dexamethasone as adjunctive
therapy to antibiotics does not inﬂuence the outcome or the complications in children as well as in adults suﬀering bacterial
meningitis. However, we identiﬁed some prognostic parameters in the outcome of bacterial meningitis, and when dexamethasone
was given in presence of at least one of 3 poor prognostic CSF parameters (WBC < 1000/mm3,g l u c o s e<20mg/dl, lactate >
10mg/dl) it substantially improved the outcome.
1.Introduction
Bacterial meningitis (BM) is still a worldwide major infec-
tious disease. About 1,2 million cases of BM are estimated
to occur annually worldwide with 135.000 deaths [1, 2].
The relative frequency of the various causes of community-
acquired meningitis has had a spectacular change over the
last 20 years. Since the introduction of Hib (Haemophilus
inﬂuenzae type b) conjugate vaccines in the developed
countries, it has resulted in a decline of invasive Hib
infections by more than 90% [3]. As a consequence
S. pneumoniae now became the leading species (47%), fol-
lowed by N. meningitidis (25%) and Listeria monocytogenes
(8%) in community-acquired meningitis in the developed
countries [4]. In the beginning of the 19th century, the
preantibiotic era, mortality rates for meningitis caused by
S. pneumoniae and Hib were 100% and for N. meningitidis
75%–80%. Since the use of third-generation cephalosporins
intheeighties,themortalityratesdroppedforpneumococcal
meningitis to 20–30%, for Hib meningitis to 5%, and for
meningococcal meningitis to 10%. But since then, there
have been little to no change in these rates, in spite of
improved diagnostic techniques, the introduction of new
antibacterials, adjunctive therapies, and progress in intensive
care [4]. With meningococcal meningitis, there is a 10–20%
chance of severe sequelae, including permanent hearing loss
and mental retardation [5–7]. Pneumococcal meningitis is
associated with high mortality and morbidity rates in adults
(30%). Whereas neurological complications are the leading
cause of death in younger patients, elderly patients die pre-
dominantly from systemic complications in pneumococcal
meningitis [8]. In children mortality is much less (7.7%–
15,3%) but they still have high prevalence of neurological
complications (25%) and hearing loss (32%) [9, 10].
It is the host’s secondary inﬂammatory response to
the entry of microorganisms into the subarachnoid space,
which produces the neuronal damage. Once entered into the
subarachnoid space, the bacteria multiply and release proin-
ﬂammatory and toxic compounds by autolysis or secretion.
AntibioticscausesrapidkillingofthebacteriaintheCSFthat
eﬀectively sterilizes the meningeal infection but enhances the
release of the proinﬂammatory and toxic compounds that
precipitatesthecytokine-mediatedinﬂammatoryresponseto
the development of cerebral oedema (cytotoxic, interstitial,
andvasogeniccerebraloedema[1,11–13]).Markedincreases
in intracranial pressure (ICP) can be deleterious in patients
with BM by causing cerebral herniation or decreasing cere-
bral perfusion and can ultimately lead to irreversible brain
injury (neuronal damage and apoptosis) and death [1]. As
a result, the therapeutic approach to BM has to be widened2 ISRN Pediatrics
from eradicating the pathogen with antibiotics to prevention
of the detrimental eﬀects of the immune response. Of
the various adjunctive therapeutic approaches to prevent
this immune response, dexamethasone has been used with
success in animal models [14, 15], in clinical trials [16–
19], and meta-analyses [20, 21]. Animal studies of BM have
shown that dexamethasone is eﬀective in minimizing the
inﬂammatoryresponsesecondarytothemeningitisinfection
in the subarachnoid space. Dexamethasone interferes with
the production of inﬂammatory compounds TNF-α and
IL-1, and limits the increase in CSF lactate and leukocyte
concentration. It also reverses development of brain oedema
and hence reduces the increase in ICP [14, 15].
We will identify some prognostic parameters that might
inﬂuence the course of BM as well as the eﬀect of the
adjunctive therapy of dexamethasone in these situations on
the complications and outcome.
2. Patientsand Methods
2.1. Patients and File Study. From 2000 to 2005, all patients
admitted in our hospital with the diagnosis of BM were
screened and studied. The patients’ data were obtained from
the hospital registry. Patients were included according to the
following inclusion criteria. The diagnosis of acute bacterial
meningitis was based on a positive gram staining or culture
oftheCSF,theCSFleukocytecountofmorethan1000/mm3,
or the presence of cloudy CSF. If the diagnosis could
be made postmortem on autopsy when lumbar puncture
was not done, patients were also included. Patients were
excluded if they had neonatal meningitis, nosocomial BM,
or antecedents of neurosurgery or neurotrauma. We did not
exclude patients who received antibiotics in the 48 hours
prior to admission, if they met the inclusion criteria.
The following parameters were studied in the patients’
ﬁles:demographiccharacteristics,predisposingfactors,clini-
calﬁndingsandbiologicalﬁndings,onadmission,treatment,
neurological, and audiological outcome, mortality, clinical
course, and adverse events.
2.2. Assessment of Outcome and Prognostic Parameters. The
population was studied for the prognostic factors associ-
a t e dw i t hap o o ro u t c o m e .P o o ro u t c o m ew a sd e ﬁ n e da s
mortality, unfavourable outcome eight weeks after discharge
(according to the Glasgow outcome scale (GOS)), hearing
loss, and focal neurological sequelae (deﬁned as ataxia,
hemiparesis, and cranial nerve palsy). The GOS [22]e i g h t
weeks after discharge was derived from the medical ﬁles. A
score of 1 indicates death, 2 a vegetative state (the patient is
unable to interact with the environment), 3 severe disability
(the patient is unable to live independently but can follow
commands), 4 moderate disability (the patient is capable
of living independently but unable to return to work or
school), and 5 minimal or no disability (the patient is able
to return to school or work). A favourable outcome was
deﬁned as a score of 5, and an unfavourable outcome as a
score of 1 to 4. Hearing loss and focal neurological sequelae
information were obtained at discharge and, where available
in the medical ﬁles, eight weeks after discharge.
2.3. Statistical Analysis. For statistical analysis SPSS 12.0
packagewasused.Theunpairedt-testwasusedtoanalysethe
diﬀerence in outcome of S. pneumoniae meningitis versus
N. meningitis meningitis in outcome (hypothesized diﬀer-
ence =0).Oddsratioand95percentconﬁdenceintervalwere
used to quantify the strength of the associations of the prog-
nostic factors for unfavourable versus favourable outcome
after 8 weeks and for presence of sequelae at discharge.
F i n a l l yA N O V Aa n dF i s h e r ’ sP L S Dt e s tw e r eu s e dt o
analyse the eﬀect of dexamethasone on the neurological
and audiological outcome in high-risk subgroups (CSF
parameters of white cell count of less than 1000/mm3,
glucose of less than 10mg/dL, and lactate of more than
10mg/dL; signiﬁcance level: 5%). A P value of less than 0,05
is considered to be signiﬁcant.
3. Results
A number of 138 patients were found with the diagno-
sis of BM. Twenty patients were withdrawn because of
neurosurgery or nosocomial BM and another 6 patients
were withdrawn because of neonatal BM. Thirteen patients
did not meet the inclusion criteria of a positive gram
staining or culture of the CSF, a CSF leukocyte count of
more than 1000/mm3, or the presence of cloudy CSF. One
patient, who had no lumbar puncture, however, with a
postmortem diagnosis on autopsy, was included. Conse-
quently we analysed a total number of 99 children and adults
who suﬀered from BM. When the diagnosis was made of
BM, based upon clinical signs or laboratory parameters,
the patients were treated with appropriate antibiotics. The
empirical therapy was ceftriaxone, ampicillin was added to
ceftriaxone if the patient was younger than 3 months of
age, or older than 60 years of age or in the presence of
immunocompromised state. A combination of ceftriaxone
plus vancomycin was used if the patient came out of a
region with resistant pneumococcal strains or in presence
of culture evidence of resistant strains. In the presence of
septic shock ﬂuid resuscitation and inotropics were added
to the treatment. In case of respiratory failure they were
intubated and mechanically ventilated. All patients received
gastric protection, by use of H2-antihistaminica.
Ninepatientsoutofthe99diedduringthecourseoftheir
disease.Fiveofthemreceiveddexamethasonewhile4ofthem
did not. The etiological pathogen was identiﬁed in 7 of them:
six of them had S. pneumoniae and 1 had N. meningitidis.S o
the mortality rate for S. pneumoniae and for N. meningitidis
was, respectively, 19% and 2%.
N. meningitidis and S. pneumoniae were the most
frequent causes of acute bacterial meningitis in our study
population, respectively, 39% and 32%. There was only one
patient in our study population, a girl of 30 months of
age, who had H. inﬂuenzae as causative organism. Listeria
monocytogenes w a sn o tf o u n da sc a u s a t i v eo r g a n i s mi na n y
patient in our population. Patients with N. meningitidis
were younger than patients with S. pneumoniae,b u tn o t
signiﬁcant.
In the total population of children and adults, 49 patients
were identiﬁed with favourable outcome (GOS of 5), whileISRN Pediatrics 3
17 patients had unfavourable outcome after 8 weeks (GOS
of 4 or less). Thirty-three patients were lost for followup.
Neurological and or audiological sequelae at discharge were
found in 21 patients while 66 patients had no sequelae
at discharge (twelve patients had no clinical data in their
medical records at discharge). Table 1 shows the association
between unfavourable outcome and Table 2 the association
between neurological or audiological sequelae and various
clinical and laboratory factors before hospitalisation, on
admission, and during hospital stay. There were several
factors with no relation to outcome or sequelae, such as age,
sex, dexamethasone treatment (see Tables 1 and 2). Various
other factors were associated with a negative outcome or
with the presence of sequelae. Unfavourable outcome and
sequelae were, respectively, 5- and 6-times more frequent if
the patients had convulsions at admission, than the patients
who had no convulsions. The presence of focal neurological
abnormalities at admission was even more associated with
worse outcome and sequelae, meaning, respectively, 10-
and 11-times more frequent. Neurological and audiological
sequelae were also associated with the presence of the triad
of symptoms at presentation of neck stiﬀness, fever, and
altered mental status. A positive gram staining or culture
for S. pneumoniae in the CSF was correlated with worse
outcome and sequelae. The laboratory parameters in the
CSF of WBC count of less than 1000/mm3, glucose less
than 20mg/dL, and lactate more than 10mmol/L were
associated with worse outcome and presence of sequelae.
Only the unfavourable outcome was associated with C-
reactive protein (CRP) in blood of more than 200mg/L
at admission and hyponatriemia (less than 130mmol/L)
in the ﬁrst 72 hours after admission. When patients were
referred from another hospital they had a higher chance for
unfavourable outcome (Table 1).
There was no diﬀerence in outcome and presence of
sequelae if dexamethasone was used. When dexamethasone
was given to patients with WBC of less than 1000/mm3
and/or glucose of less than 20mg/dL and/or lactate of
more than 10mmol/L in the CSF, they had signiﬁcantly
better outcome. Unfavourable outcome after 8 weeks was
signiﬁcantly less in patients that received dexamethasone
who had at least one of these 3 conditions. In these con-
ditions there was an 84,7% chance for favourable outcome
deﬁned as GOS of 5, and 17,3% chance for unfavourable
outcome when dexamethasone was administered. When
no dexamethasone was given, there was only a chance of
43,2% of good outcome, and 56,8% chance of unfavourable
outcome. The mortality rate was not signiﬁcantly aﬀected by
use of dexamethasone in one of these conditions (P = 0,12).
4. Discussion
In accordance with the literature the common causative
organisms of BM in our study were S. pneumoniae and
N. meningitidis. The mortality rate for S. pneumoniae and
for N. meningitidis was slightly lower than reported in the
literature [4, 20] .T h eo v e r a l lo u t c o m ew a sw o r s ei nB M
with S. pneumoniae than with N. meningitidis and this is
comparable to the literature data [5, 8–10].
Asshowninpreviousstudiesthepresenceofconvulsions,
focal neurological abnormalities, or impaired consciousness
at admission are strongly associated with adverse outcome
and sequelae [8, 23–28]. While the triad of symptoms (neck
stiﬀness, altered mental status, and fever) was only present
in 25 percent of the patients, this triad was associated
with neurological or audiological sequelae, as comparable
to the literature [23]. However, our population consisted
of both children and adults, and the low rate of presence
of the classic triad at presentation was often observed in
the children group. In the age group younger than 12
months neckstiﬀness is not always an interpretable clinical
sign. When the patients had petechial rash on admission,
there was a positive association with good outcome and
the absence of sequelae, as in the literature data [23,
29]. Reﬂecting that petechiae are more associated with N.
meningitidis, and this pathogen has a better outcome in
bacterial meningitis, compared to S. pneumoniae.Al o wC S F
WBC count was associated with an adverse outcome. This
wasduetoafulminantmeningococcalsepsisandmeningitis.
This association has been described earlier [8, 23, 26, 27, 30].
The laboratory parameters in the CSF, glucose less than
20mg/dL, and lactate more than 10mmol/L were associated
with worse outcome and presence of sequelae, this was also
found in adults and children literature [23, 29, 31, 32]. In
our study unfavourable outcome was also associated with C-
reactive protein (CRP) in blood of more than 200mg/L on
admission and hyponatriemia (less than 130mmol/L) in the
ﬁrst 72 hours after admission.
We found that dexamethasone was more eﬀective in sit-
uations were WBC count was low in the CSF (<1000/mm3).
Although a high WBC count in the CSF is correlated with a
high inﬂammatory response, and dexamethasone interferes
with this inﬂammatory reaction. A low WBC count in the
CSF probably means excessive bacterial growth and insuf-
ﬁcient leukocyte response, hence increased complications
[8, 23, 26, 27, 30], explaining our results. In accordance with
our study, CSF levels of WBC count less than 1000/mm3,
glucoselessthan20mg/dL,andlactatemorethan10mmol/L
in CSF dexamethasone treatment, were able to reduce
complications. But further studies are needed to support
these ﬁndings. A recent published trial of BM in adults
[19] also showed that patients with a GCS between 8 to
11 on admission have a better neurological outcome when
dexamethasone was administered.
The above prognostic parameters, together with the evi-
denceof beneﬁcialeﬀectofdexamethasone in pneumococcal
meningitis, might help to identify those patients who will
utmost beneﬁciate from dexamethasone therapy.
Routine use of dexamethasone is now increasingly used
in children and adults with BM. Although beneﬁt was not
proven in all etiological subgroups (mainly N. meningitidis),
failure to demonstrate an eﬀe c ti sm o r el i k e l yd u et ot h e
limited power from low event rates and limited size of the
studied populations in the literature. The pathophysiological
mechanisms that result in CNS damage seems to be similar
in the diﬀerent etiological organisms. They all stimulate
the production of TNF-α and IL-1, which are suppressed
by administration of dexamethasone. Therefore why should4 ISRN Pediatrics
Table 1: Prognostic factors for unfavourable versus favourable outcome after 8 weeks.
Unfavourable
(n = 17)
Favourable
(n = 49)
Odds ratio
(95% CI)∗
Age (yr)—mean ± SD 21 ± 30 20 ± 32 —
Males—% 65 51 —
Duration symptoms before admission (hr)—mean ± SD 45 ± 45 34 ± 41 —
Duration symptoms before admission <24hrs—no./tot. no. (%) 10/17 (59) 36/48 0.48 (0.15–1.53)
Received dexamethasone—no./tot. no. (%) 11/17 (65) 33/49 (67) 0.89 (0.18–2.84)
Received AB in last 48hr—no./tot. no. (%) 4/17 (24) 9/48 (19) 1.33 (0.35–5.06)
Coexisting conditions—no./tot. no. (%)
Otitis/sinusitis 2/17 (12) 15/49 (31) 0.30 (0.061–1.49)
Pneumoniae 3/17 (18) 4/49 (8) 2.41 (0.48–12.09)
Immunocompromise 4/17 (24) 3/49 (6) 4,72 (0,96–23,8)
Convulsions on admission—no./tot. no. (%) 7/17 (41) 6/49 (12) 5,0(1,4–18,2)
Findings on admission—no./tot. no. (%)
Normal consciousness 2/17 (12) 31/49 (63) 0,07(0,02–0,38)
GCS score < 8 4/10 (40) 2/40 (5) 12.67 (1.89–84.97)
Focal neurological signs 5/17 (29) 2/49 (4) 9,8(1,69–56,8)
Temperature > 38◦C 13/17 (76) 34/48 (71) 1.34 (0.37–44.82)
Triad (neck stiﬀness, fever, and altered mental status) 4/11 (36) 10/35 (28) 1.43 (0.34–5.97)
Petechiae 1/17 (6) 21/49 (43) 0,08(0,01–0,68)
CSF culture—no./tot. no. (%)
S. pneumonia 12/17 (70) 15/49 (31) 5,44(1,62–18,2)
N. meningitidis 3/17 (18) 17/49 (35) 0,4 (0,102–1,60)
Other bacteria 1/17 (6) 8/49 (16) 0.32 (0.037–2.77)
Negative culture 1/17 (6) 9/49 (18) 0.28 (0.032–2.37)
CSF parameters
Positive bacterial culture—no./tot. no. (%) 16/16 (100) 38/49 (78) —
WBC (/mm3)—mean ± SD 3401 ± 7211 6057 ± 8156 —
WBC < 1000/mm3—no./tot. no. (%) 10/13 (77) 15/49 (31) 7,6(1,82–31,4)
Proteins (mg/dL)—mean ± SD 558 ± 557 305 ± 263 —
Proteins > 500mg/dL—no/tot no (%) 6/13 (46) 12/49 (24) 2,64 (0,74–9,39)
Glucose (mg/dL)—mean ± SD 18,5 ± 21,8 35,6 ± 25,1 —
Glucose < 20mg/dL—no/tot no (%) 11/13 (85) 20/49 (41) 7,98(1,59–39,9)
Glucose CSF/serum ratio (%)—mean ± SD 16 ± 14 28 ± 20 —
Lactate (mmol/L)—mean ± SD 12,3 ± 4,9 8,0 ± 5,0 —
Lactate > 10mmol/L—no./tot. no. (%) 7/9 (78) 15/44 (34) 6,77(1,25–36,7)
Positive blood culture, no./tot. no. (%) 9/16 (56) 22/48 (56) 1.52 (0.49–4.75)
Blood parameters
Hb∗∗ (g/dL)—mean ± SD 10,8 ± 2,4 12,0 ± 1,9 —
Platelets (×103/mm3)—mean ± SD 269 ± 143 280 ± 148 —
CRP∗∗∗ (mg/L)—mean ± SD 258 ± 119 176 ± 128 —
CRP > 200mg/L—no./tot. no. (%) 12/17 (70) 19/49 (39) 3,78(1,15–12,5)
Hyponatremia∗∗ in ﬁrst 72u—no./tot. no. (%) 4/17 (24) 2/49 (4) 7,23(1,19–43,9)
Referred from an other hospital—no./tot. no. (%) 10/17 (59) 9/49 (18) 6,35 (1,9–21,2)
∗CI = conﬁdence interval, ∗∗Hb = haemoglobin, ∗∗∗CRP = C-reactive protein.ISRN Pediatrics 5
Table 2: Prognostic factors for neurological or audiological sequelae at discharge.
Neuro/audio sequel
(n = 21)
No sequel
(n = 66)
Odds ratio
(95% CI)
Age (yr)—mean ± SD 19 ± 26 15 ± 20 —
Males—% 57 47 —
Duration symptoms before admission (hr)—mean ± SD 44 ± 51 33 ± 39 —
Duration symptoms before admission < 24hrs—no./tot. no. (%) 14/21 (67) 49/64 (76) 0.61 (0.21–1.80)
Received Dexamethasone—no./tot. no. (%) 16/21 (76) 46/66 (70) 1.39 (0.45–4.32)
Received AB in last 48hr—no./tot. no. (%) 5/21 (24) 7/65 (11) 2.59 (0.72–9.26)
Coexisting conditions—no/tot no (%)
Otitis/sinusitis 6/21 (28) 11/66 (17) 2.00 (0.66–6.30)
Pneumoniae 3/21 (14) 3/66 (4) 3.5 (0.65–18.85)
Immunocompromise 0/21 5/66 (8) —
Convulsions on admission—no./tot. no. (%) 7/21 (33) 5/66 (8) 6.10 (1.69–22.08)
Findings on admission—no./tot. no. (%)
Normal consciousness 7/21 (33) 45/64 (70) 0.21 (0.074–0.60)
GCS score < 8 0/11 3/50 (6) —
Focal neurological signs 3/21 (14) 1/66 (2) 10.83 (1.06–110.53)
Temperature > 38◦C 17/21 (81) 44/65 (68) 2.03 (0.61–6.78)
Triad (neck stiﬀness, fever, and altered mental status) 7/13 (54) 9/52 (17) 5.57 (1.51–20.57)
Petechiae 4/21 (19) 36/66 (54) 0.20 (0.060–0.64)
CSF culture—no./tot. no. (%)
S. pneumoniae 14 (67) 11 (17) 10 (3.28–30.48)
N. meningitidis 3 (14) 33 (50) 0.17 (0.045–0.62)
Other bacteria 2 (10) 7 (11) 0.84 (0.17–4.64)
Negative culture 2 (10) 15 (23) 0.36 (0.075–1.72)
CSF parameters
Positive bacterial culture—no./tot. no. (%) 18/21 (86) 50/66 (76) 1.92 (0.50–7.37)
WBC (/mm3)—mean ± SD 2805 ± 4891 5763 ± 7845 —
WBC < 1000/mm3—no./tot. no. (%) 11/18 (61) 21/64 (33) 3.22 (1.09–9.49)
Proteins (mg/dL)—mean ± SD 325 ± 248 262 ± 238 —
Proteins > 500mg/dL—no./tot. no. (%) 5/18 (28) 12/61 (20) 1.57 (0.47–5.26)
Glucose (mg/dL)—mean ± SD 22,2 ± 18,3 42,0 ± 26,3 —
Glucose < 20mg/dL—no./tot. no. (%) 11/18 (61) 20/62 (32) 3.30 (1.11–9.78)
Glucose CSF/serum ratio (%)—mean ± SD 21 ± 17 33 ± 22 —
Lactate (mmol/L)—mean ± SD 9,9 ± 4,4 7,9 ± 6,3 —
Lactate > 10mmol/L—no./tot. no. (%) 10/16 (62) 12/48 (25) 5(1.50–16.68)
Positive blood culture—no./tot. no. (%) 9/20 (45) 33/63 (52) 0.74 (0.27–2.04)
Blood parameters
Hb (g/dL)—mean ± SD 11 ± 21 2 ± 2 —
Platelets (×103/mm3)—mean ± SD 291 ± 141 270 ± 136 —
CRP (mg/L)—mean ± SD 218 ± 134 172 ± 128 —
CRP > 200mg/L—no./tot. no. (%) 11/21 (52) 23/66 (35) 2.06 (0.76–5.56)
Hyponatremia in ﬁrst 72u—no./tot. no. (%) 3/21 (14) 3/66 (4) 3.5 (0.65–18.85)
Referred from another hospital—no./tot. no. (%) 7/21 (33) 27/66 (41) 0.72 (0.26–2.03)6 ISRN Pediatrics
dexamethasone not have the same beneﬁcial eﬀect in
meningococcal meningitis as in Hib and S. pneumoniae
meningitis?
S. pneumoniae as an etiological cause and a GCS on
admissionof8to11havealreadybeenidentiﬁedassituations
where dexamethasone is more beneﬁcial. [19].
In this retrospective study we found that in presence
of at least one of 3 CSF parameters (WBC < 1000/mm3,
glucose< 20mg/dL, and lactate > 10mg/dL) dexamethasone
wouldhavethemostbeneﬁcialeﬀect.However,intheclinical
setting, dexamethasone and antibiotics are most frequently
given when bacterial meningitis is suspected before the
causative germ is known.
In view of this retrospective analysis with its limitations,
more studies are needed to conﬁrm the results and, more-
over, to detect a possible beneﬁcial eﬀect of dexamethasone
therapy in patients with meningococcal meningitis. The
prospect of clinical trials in children, already limited by small
case numbers, will be further reduced since the decline in
invasive pneumococcal and meningococcal (serogroup C)
infections in children as a result of the implementation of
the vaccines.
5. Conclusions
We identiﬁed 3 prognostic parameters (WBC < 1000/mm3,
glucose < 20mg/dL, and lactate > 10mg/dL) which seems to
be associated with poor outcome in BM. Administration of
adjunctive dexamethasone therapy in these condition would
have most beneﬁcial eﬀect on the outcome.
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